Back to top
April
27
2017

Becton Dickinson acquires C.R. Bard for $24 billion

In a medical technology merger with implications for the healthcare sector in the United States and beyond, Becton Dickinson is acquiring C.R. Bard for $24…

Read More
April
19
2017

Zoetis Builds on Biologics Pipeline with $85M Nexvet Acquisition

Zoetis announced on Thursday that it is acquiring Ireland-based Nexvet Biopharma in an $85 million deal that will bring new biologic drug candidates to the…

Read More
April
11
2017

Genzyme CEO Steps Down as Dupixent is Approved

David Meeker, Sanfoi’s EVP and CEO of the Genzyme unit, will step down in June. The news came right after Sanofi and partner Regeneron gained…

Read More
March
1
2017

Orphan drugs attract rich returns for pharmaceuticals

When the US biotech company Genzyme started selling its treatment for a rare disorder called Gaucher’s disease at up to $300,000 per patient a year,…

Read More
February
21
2017

Top 10 U.S. patent losses of 2017

Among the many meds that’ll lose patent protection in the U.S. this year are 10 drugs that each contribute in a big way for top…

Read More
February
20
2017

Sage Therapeutics fuels, then dampens, its own M&A rumors

In an interview with Bloomberg published yesterday, Sage CEO Jeff Jonas was quoted as saying his company was at the top of everyone’s buying list, sending…

Read More
"Every science begins as philosophy and ends as art." Will Durant,